Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 6221-6230 Newer>

The Motley Fool March 9, 2005 Lawrence Meyers	Pediatrix Misses by a Heartbeat A small earnings miss hits Pediatrix stock, but the pediatric critical care provider is healthier than it looks.
The Motley Fool March 9, 2005 Stephen D. Simpson	The Future of the China Syndrome What will China's saber-rattling do to Taiwanese companies? While every investor must of course do his or her own due diligence, anyone who'd been waiting for an opportunity to get into Taiwan may have just been given an opening.
The Motley Fool March 9, 2005 Steven Mallas	CVS Comps Feast on Flu CVS enjoys a nice jump in same-store sales for the month of February -- thanks, in part, to colds and the flu.
The Motley Fool March 9, 2005 Stephen D. Simpson	Landry's Gamble Will this restaurant operator strike gold with the Golden Nugget, or will it be a fish out of water? Investors looking at Landry's have to decide whether to hold 'em or fold 'em.
The Motley Fool March 9, 2005 Rich Smith	Asset Seeks Acceptance Debt collector spooks the market with a huge secondary offering.
The Motley Fool March 9, 2005 Tom Taulli	McGraw-Hill Gains Power At age 73, it was time for J.D. Power III to find an exit. In this case, the buyer of the marketing information firm was another renowned family business, McGraw-Hill. But the deal-making means a short-term negative for the publisher.
The Motley Fool March 9, 2005 Stephen D. Simpson	The Merits of Merit Medical Living in the gaps created by the big boys is risky for small medical device makers, but it can pay off over time. Merit Medical could hold some merit for patient value portfolios.
The Motley Fool March 9, 2005 Jeremy MacNealy	A Finger-Lickin' Good Stock? Famous Dave's has some tasty ribs, but owning its stock might be an acquired taste.
The Motley Fool March 9, 2005 Alyce Lomax	Tenacious Talbots This outfit still doesn't quite match up. Fourth-quarter earnings fell 27% to $16 million, or $0.29 per diluted share.
The Motley Fool March 9, 2005 Bill Mann	Crompton Acquires Great Lakes A merger of two major niche chemical companies apparently gains approval. Investors signaled approval for the deal by sending both companies' shares substantially higher.
<Older 6221-6230 Newer> Return to current articles.